Novo Nordisk’s stock tumbles as drugmaker lays out case for declining sales in 2026
The maker of Ozempic and Wegovy blamed pricing pressures and competition for its downbeat outlook.
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief
